EHA 2022 | The use of radiopharmaceuticals in R/R AML
David Sallman, MD, Moffit Cancer Center, Tampa, FL, talks on the use of radioisotopes in the treatment of acute myeloid leukemia (AML), commenting on the Phase III SIERRA study (NCT02074839) evaluating Iomab-B, a radio-immunotherapy, prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in older patients with relapsed/refractory (R/R) AML. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Incyte: Speakers Bureau; AbbVie: Membership on an entity’s Board of Directors or advisory committees; Aprea: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Bristol-Myers Squibb: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Agios: Membership on an entity’s Board of Directors or advisory committees; Intellia: Membership on an entity’s Board of Directors or advisory committees; Kite: Membership on an entity’s Board of Directors or advisory committees; Magenta: Consultancy; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Syndax: Membership on an entity’s Board of Directors or advisory committees; Shattuck Labs: Membership on an entity’s Board of Directors or advisory committees; Takeda: Consultancy.
